Overview A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects. Status: Completed Trial end date: 2021-08-31 Target enrollment: Participant gender: Summary To evaluate the safety, tolerability and Pharmacokinetic profile of SNP-630 when oral administered to healthy subjects. Phase: Phase 1 Details Lead Sponsor: Sinew Pharma Inc.